LL-37 Dosage Chart & Schedule
The only human cathelicidin antimicrobial peptide, studied for direct antimicrobial activity as well as roles in inflammation and wound healing. Human therapeutic use is investigational.
LL-37 is the only human cathelicidin antimicrobial peptide, studied for antimicrobial, anti-inflammatory, and wound-healing activity almost entirely in preclinical models. There is no established human dosing; research-community references cite small subcutaneous amounts, but these are unvalidated.
Figures describe how LL-37 is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Not established
- Weekly total
- Not established
- Cycle
- Not established
Work is largely preclinical; LL-37 is rapidly degraded by proteases, which complicates dosing.
Preclinical / research-only
- No established human dosing; studies span antimicrobial, wound-healing, and immunomodulatory models.
- Rapidly degraded by proteases, so systemic exposure is short-lived.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe.
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- If a research vial is used, reconstitute with bacteriostatic water (a 5 mg vial in about 2 mL gives 2,500 mcg/mL); the small amounts referenced draw up as a fraction of a millilitre.
- There is no validated human regimen; figures are research-community references only.
- Refrigerate the reconstituted solution and keep lyophilized material frozen.
LL-37 dosing FAQ
Is there an established human dose for LL-37?
No. The evidence base is largely preclinical, so no validated human dose or schedule exists.
What amounts do research sources reference?
Research-community sources cite small subcutaneous amounts, roughly 100-1000 mcg, but these are unvalidated rather than a recommended dose.
Why is the dosing so heavily hedged?
LL-37 is protease-labile and studied mostly in cell and animal models, so any human figure is a rough reference at best.
Sources
Categories: Immune & Gut · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.